Zai Lab inks China deal with Turning Point with $25M upfront; Xencor, Atreca team up on bispecifics
→ Zai Lab is paying out a $25 million upfront for the rights to sell Turning Point Therapeutics’ lead drug repotrectinib in Greater China. The San Diego-based biotech is also in line for up to $151 million in milestones, along with mid-to-high teen royalties. Zai plans to add sites to the Phase II trial of the drug, which is designed to treat ROS1-positive advanced NSCLC in patients who were not previously treated with a TKI.
→ Xencor and Atreca forged a collaboration and license deal to research, develop and commercialize T cell engaging bispecific antibodies as potential therapeutics in oncology. Atreca will provide antibodies against novel tumor targets while Xencor engineers XmAb bispecific antibodies that also bind to the CD3 receptor on T cells: “Up to two joint programs will be mutually selected for further development and commercialization, with each partner sharing 50 percent of costs and profits. Each company will lead development, regulatory and commercialization activities for one of the joint programs. In addition, the agreement allows for each partner to pursue up to two programs independently, with a mid- to high-single digit percent royalty payable on net sales. Atreca and Xencor began working together in 2019 under a material transfer agreement to accelerate this new collaboration agreement.”
→ Dialing up the application of AI in its drug discovery work, Roche has enlisted Cambridge, MA-based Reverie Labs for a multi-target collaboration to screen and optimize inhibitors of several kinases. James Sabry, head of pharma partnering, is apparently in for the long run with Reverie Labs’ platform, which generates millions of chemical structures to choose from.
→ Takeda is licensing a phage display “library of libraries” from Twist Bioscience to search for, validate and optimize its antibody pipeline. The deal covers the core areas of oncology, rare diseases, neuroscience and gastroenterology.
→ Roche’s Chugai subsidiary is teaming up with Thermo Fisher to develop a companion diagnostic for Rozlytrek in Japan, which has been approved in the country for ROS1-positive non-small cell lung cancer.